Raymond Hohl, MD, PhD - Penn State Cancer Institute
Researcher Profile
Raymond Hohl, MD, PhD
University Professor in Oncology, Department of Medicine
Division of Hematology and Oncology
Professor, Department of Molecular and Precision Medicine
One Health Microbiome Center
Division of Hematology and Oncology
Professor, Department of Molecular and Precision Medicine
One Health Microbiome Center
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Bone Marrow Transplantation Team
Cancer Institute, Leukemia and Lymphoma Team
Cancer Institute, Leukemia and Lymphoma Team
Clinical Trials
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
A Phase I/II Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (KRYSTAL-1) (MRT849-001)
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
NRG HN009- Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Protocol for a Research Database for Hematopoietic Cell Transplantation, other Cellular Therapies and Marrow Toxic Injuries.
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Recent Publications
2024
Zulch, E, Inoue, Y, Cioccio, J, Rakszawski, K, Songdej, N, Nickolich, M, Zheng, H, Naik, S, Rybka, W, Ehmann, C, Sivik, J, Mierski, J, Silar, B, Vajdic, C, Greiner, R, Brown, V, Hohl, R, Claxton, D, Shike, H, Paules, CI, Mineishi, S & Minagawa, K 2024, 'Impact of post-transplant cyclophosphamide and splenomegaly on primary graft failure and multi-lineage cytopenia after allogeneic hematopoietic cell transplantation', Leukemia Research, vol. 143, 107530. https://doi.org/10.1016/j.leukres.2024.107530
Khosla, A, Inoue, Y, Cioccio, J, Rakszawski, K, Songdej, N, Nickolich, M, Zheng, H, Naik, S, Ehmann, C, Claxton, D, Rybka, W, Sivik, J, Mierski, J, Silar, B, Vajdic, C, Hohl, R, Shike, H, Mineishi, S & Minagawa, K 2024, 'Recurrent disease after a matched sibling hematopoietic transplant in an aplastic anemia patient with a disease risk allele, HLA-B*40:02', Blood Transfusion, vol. 22, no. 6, pp. 525-528. https://doi.org/10.2450/BloodTransfus.674
Guare, EG, Hale, CM, Sivik, J, Lehman, E, Inoue, Y, Rakszawski, K, Songdej, N, Nickolich, M, Zheng, H, Naik, S, Claxton, D, Rybka, W, Hohl, R, Mineishi, S, Minagawa, K & Paules, CI 2024, 'The addition of doxycycline to fluoroquinolones for bacterial prophylaxis in autologous stem cell transplantation for multiple myeloma', Transplant Infectious Disease, vol. 26, no. 2, e14241. https://doi.org/10.1111/tid.14241
2022
ELOQUENT-1 investigators 2022, 'Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial', The Lancet Haematology, vol. 9, no. 6, pp. e403-e414. https://doi.org/10.1016/S2352-3026(22)00103-X
Manfredi, B, Neighbors, JD & Hohl, RJ 2022, 'Cytotoxic Effects of the Schweinfurthin Analog 5'-Methylschweinfurthin G in Malignant Plasma Cells', Pharmacology, vol. 107, no. 9-10, pp. 510-523. https://doi.org/10.1159/000525299
Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Shah, N, Tuanquin, L, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Shike, H 2023, 'Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis', Annals of Hematology, vol. 102, no. 3, pp. 613-620. https://doi.org/10.1007/s00277-022-05077-2
Shah, N, Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Mierski, J, Zhou, S, Shike, H, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Tuanquin, L 2022, 'Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide', Leukemia Research, vol. 123, 106969. https://doi.org/10.1016/j.leukres.2022.106969
Zhao, C, Bartock, M, Jia, B, Shah, N, Claxton, DF, Wirk, B, Rakszawski, KL, Nickolich, MS, Naik, SG, Rybka, WB, Ehmann, WCC, Hohl, RJ, Valentin, J, Bernas-Peterson, M, Gerber, EM, Zimmerman, M, Mierski, JA, Mineishi, S & Zheng, H 2022, 'Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant', Journal of Hematology and Oncology, vol. 15, no. 1, 64. https://doi.org/10.1186/s13045-022-01287-3
Weissenrieder, JS, Weissenkampen, JD, Reed, JL, Green, MV, Zheng, C, Neighbors, JD, Liu, DJ & Hohl, RJ 2022, 'RNAseq reveals extensive metabolic disruptions in the sensitive SF-295 cell line treated with schweinfurthins', Scientific reports, vol. 12, no. 1, 359. https://doi.org/10.1038/s41598-021-04117-7
Zhang, R, Neighbors, JD, Schell, TD & Hohl, RJ 2022, 'Schweinfurthin induces ICD without ER stress and caspase activation', OncoImmunology, vol. 11, no. 1, 2104551. https://doi.org/10.1080/2162402X.2022.2104551
Koubek, EJ, Weissenrieder, JS, Ortiz, LE, Nwogu, N, Pham, AM, Weissenkampen, JD, Reed, JL, Neighbors, JD, Hohl, RJ & Kwun, HJ 2022, 'Therapeutic Potential of 5′-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma', Viruses, vol. 14, no. 9, 1848. https://doi.org/10.3390/v14091848
2021
Weissenrieder, JS, Reed, JL, Moldovan, GL, Johnson, MT, Trebak, M, Neighbors, JD, Mailman, RB & Hohl, RJ 2021, 'Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D2 receptor-dependent, manner', Pharmacology Research and Perspectives, vol. 9, no. 3, e00689. https://doi.org/10.1002/prp2.689